Abstract：
:Anaplastic oligodendrogliomas are rare primary brain tumors. However, they respond more effectively to treatment and have a better prognosis than commoner varieties. About 25 year ago, reports emerged that oligodendrogliomas can respond robustly and durably to chemotherapy with procarbazine, lomustine (CCNU), and vincristine (PCV). It was also discovered that co-deletion of chromosome arms 1p and 19q is more commonly observed in oligodendrogliomas (rather than astrocytomas). Early results of phase III trials confirmed that 1p/19q co-deletion was a favorable prognostic marker. Mature results now conclusively demonstrate that co-deletion also predicts longer survival from the addition of PCV chemotherapy to radiotherapy for newly diagnosed disease. However, changes in the treatment landscape, including a preference for deferred radiotherapy, the emergence of temozolomide as a better tolerated chemotherapy regimen, and the discovery of other biomarkers (e.g. IDH mutation and MGMT promoter methylation) that occurred in the interim emphasize the need for earlier, validated, and acceptable trial end points.
journal_name
Curr Oncol Repjournal_title
Current oncology reportsauthors
Lassman ABdoi
10.1007/s11912-012-0281-5subject
Has Abstractpub_date
2013-02-01 00:00:00pages
47-55issue
1eissn
1523-3790issn
1534-6269journal_volume
15pub_type
杂志文章abstract：PURPOSE OF REVIEW:Glioblastoma (GBM) is the most common and lethal primary brain tumor in adults, with a median survival of less than 2 years despite the standard of care treatment of 6 weeks of chemoradiotherapy. We review the data investigating hypofractionated radiotherapy (HFRT) in the treatment of newly diagnosed ...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-017-0616-3
更新日期：2017-09-01 00:00:00
abstract：:The search is on for biomarkers for use in the diagnosis, staging, prognosis, and management of patients with melanoma. As with many types of cancer, the hematogenous spread of melanoma is a bad prognostic sign, and many groups have attempted to detect circulating melanoma cells in patients with different stages of me...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-005-0065-2
更新日期：2005-09-01 00:00:00
abstract：:Overall survival for patients with squamous cell carcinoma of the head and neck (SCCHN) has not improved appreciably over the past few decades. Because standard treatments have not controlled this disease with sufficiently high success rates, novel therapeutic approaches, such as immunotherapy, are under investigation...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-008-0025-8
更新日期：2008-03-01 00:00:00
abstract：:The topoisomerase I inhibitors such as irinotecan and topotecan are active agents against small-cell lung cancer that are effective in treating not only chemotherapy-naïve tumors but also progressed-stage tumors after treatment with cisplatin-based regimens, because their mechanism of antitumor activity differs from t...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-001-0018-3
更新日期：2001-03-01 00:00:00
abstract：:Management of tumors of the salivary glands requires a detailed understanding of the anatomy and pathologic processes affecting these glands. Salivary glands give rise to benign and malignant neoplasms and are affected by a variety of systemic diseases. CT remains the most common primary imaging study; magnetic resona...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-007-0011-6
更新日期：2007-03-01 00:00:00
abstract：:High-risk non-melanoma skin cancer (NMSC) of the head and neck is difficult to manage, given its propensity for regional metastasis, perineural invasion, direct parotid invasion, and bony destruction. Management of these tumors demands awareness of the characteristics contributing to their recurrence. Recent studies e...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-005-0042-9
更新日期：2005-03-01 00:00:00
abstract：:The success of the angiogenesis inhibitor bevacizumab, the vascular endothelial growth factor antagonist that was recently shown to significantly improve the survival of patients with metastatic colon cancer when administered in combination with conventional chemotherapy, has provided proof of principle in clinical tr...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-996-0008-6
更新日期：2004-01-01 00:00:00
abstract：:Malignant pleural effusions (MPEs) are a significant source of cancer-related morbidity. Over 150,000 patients in the United States suffer from breathlessness and diminished quality of life due to MPE each year. Current management strategies are of mostly palliative value and focus on symptom control; they do not addr...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-013-0315-7
更新日期：2013-06-01 00:00:00
abstract：:Management of early endometrial cancer is contentious these days with little agreement between oncologists as well as across MDTs or tumour boards and indeed across countries. This is because of the state of knowledge with regards to risk factors in early endometrial cancer; although we recognise risk factors affect o...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-016-0505-1
更新日期：2016-04-01 00:00:00
abstract：:Pediatric medicine is moving toward a greater appreciation that the delivery of quality medical care involves a partnership including the health care team, the child, and the family. Pediatric medicine now emphasizes the importance of information exchange among these groups. This paper discusses two models for communi...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-007-0061-9
更新日期：2007-11-01 00:00:00
abstract：:Proton beam radiation therapy (PBRT) has unique physical properties (e.g., Bragg Peak) that limit the amount of normal tissue irradiated in the head and neck region while maximizing the radiation delivered to the tumor. Radiation therapy is commonly used in both the primary and adjuvant setting for many head and neck ...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-010-0089-0
更新日期：2010-05-01 00:00:00
abstract：:Treatment with cytotoxic chemotherapy and radiotherapy is associated with significant gonadal damage in men and women. The likelihood of gonadal failure following cytotoxic chemotherapy is dependent on the drug and dose, and in women there is also an effect of age at treatment. Irradiation of the testes or ovaries, ei...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-002-0039-6
更新日期：2002-09-01 00:00:00
abstract：:Options for treatment of poor-prognosis or relapsed acute myeloid leukemia (AML) remain limited. Gemtuzumab ozogamicin (Mylotarg, Wyeth-Ayerst, Philadelphia, PA) is an immunoconjugate composed of recombinant humanized murine anti-CD33 antibody linked to calicheamicin, a potent cytotoxic agent. Phase II trials have sho...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-002-0030-2
更新日期：2002-09-01 00:00:00
abstract：:The original version of this article, which published in Current Oncology Reports, Volume 21, Issue 6, June 2019, contained an error in addressing the indication for use of neratinib in early stage breast cancer. ...
journal_title：Current oncology reports
pub_type： 已发布勘误
doi：10.1007/s11912-019-0813-3
更新日期：2019-05-17 00:00:00
abstract：:The diagnosis of a gynecological malignancy during pregnancy is rare but not uncommon. Cancer treatment during pregnancy is possible, but both maternal and fetal interests need to be respected. Different treatment plans may be justifiable and multidisciplinary treatment is advised. Clinical trials are virtually imposs...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-014-0415-z
更新日期：2014-12-01 00:00:00
abstract：:Inter-individual variability in carcinogen metabolism has been attributed in part to the polymorphic expression of several phase I and II detoxification enzymes. The role of these genetic polymorphisms in cancer susceptibility has been most extensively evaluated for isozymes of cytochrome P450 (CYP1A1, CYP2D6, and CYP...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-000-0075-z
更新日期：2000-05-01 00:00:00
abstract：PURPOSE OF REVIEW:Skull base reirradiation is challenging due to complex anatomy, enrichment of treatment-resistant clonogens, and increased risk of severe treatment complications. Without local therapy, early mortality is certain and tumor progression can result in debilitating symptoms. Modern radiotherapy advancemen...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-017-0639-9
更新日期：2017-10-28 00:00:00
abstract：PURPOSE OF REVIEW:The concept of value-based health care (VBHC) was articulated more than a decade ago. However, its clinical implementation remains an on-going process and a particularly demanding one for the domain of head and neck cancer (HNC). These cancers often present with fast growing tumors in functionally and...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-020-00952-5
更新日期：2020-07-10 00:00:00
abstract：:Primary and metastatic spinal mesenchymal tumors are uncommon lesions. Surgical management of these tumors remains a challenge. En bloc wide resection provides the best chance for local tumor control and long-term survival. However, limitations to this technique include technical considerations (including neurovascula...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-006-0036-2
更新日期：2006-07-01 00:00:00
abstract：:The treatment of non-Hodgkin lymphoma (NHL) has changed dramatically since the introduction of rituximab, a monoclonal antibody that binds to the B-cell transmembrane protein CD20 and causes lysis of the lymphoma cells. Since then, a number of additional antibodies have been tested against other B-cell targets, result...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-008-0064-1
更新日期：2008-09-01 00:00:00
abstract：PURPOSE OF REVIEW:Pancreatic adenocarcinoma is a leading cause of cancer mortality in western countries with a uniformly poor prognosis. Unfortunately, there has been little in the way of novel therapeutics for this malignancy over the last several decades. Derangements in metabolic circuitry favoring excess glycolysis...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-018-0699-5
更新日期：2018-05-11 00:00:00
abstract：:Dysregulation of the cell cycle is a classic hallmark of cancer growth and metastatic potential. Re-establishing cell cycle control through CDK inhibition has emerged as an attractive option in the development of targeted cancer therapy. Three oral agents selectively targeting CDK4/6 have been developed: palbociclib, ...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-015-0443-3
更新日期：2015-01-01 00:00:00
abstract：:Lung cancer is the most common cause of cancer death worldwide. The overall 5-year survival rate remains disappointing at 14% or less. Several clinician- and community-based interventions show promise for reducing lung cancer incidence through prevention and smoking cessation. However, long-term heavy smokers retain a...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-002-0060-9
更新日期：2002-11-01 00:00:00
abstract：:Aflibercept (known as ziv-aflibercept in the USA and sold under the trade name Zaltrap®) is a human recombinant fusion protein with antiangiogenic effects that functions as a decoy receptor to bind vascular endothelial growth factors A and B and placental growth factor. Its unique mechanism of action with respect to o...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-013-0368-7
更新日期：2014-02-01 00:00:00
abstract：:Gastrointestinal stromal tumors (GISTs) are the most common soft tissue sarcoma, and most feature abnormalities in two genes encoding the receptor tyrosine kinases (RTKs), KIT, and PDGFRA. The RTK inhibitor imatinib revolutionized treatment in GIST; however, drug resistance remains a challenge. Constitutive autophosph...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-013-0316-6
更新日期：2013-08-01 00:00:00
abstract：:With our understanding of human papillomavirus (HPV) and cervical cancer, the availability of HPV testing, and the known limitations of cervical cytology, it is time to reassess cervical cancer screening technologies. This article reviews recent randomized trials comparing primary HPV testing with cervical cytology in...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-008-0081-0
更新日期：2008-11-01 00:00:00
abstract：:There is no clear consensus regarding the most effective management of poor responders to neoadjuvant chemotherapy. Intensifying or changing primary systemic treatment has not been shown to offer any benefit. There is a paucity of trials testing the utility of adjuvant chemotherapy in this setting. Adjuvant hormonal t...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-009-0007-5
更新日期：2009-01-01 00:00:00
abstract：:Epidemiologic studies supported by molecular technology have provided sufficient evidence of the causal role of some human papillomavirus (HPV) infections in the development of cervical cancer. The finding is consistent universally, and HPV has been proposed as the first identified necessary cause of cervical cancer. ...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-002-0079-y
更新日期：2002-03-01 00:00:00
abstract：PURPOSE REVIEW:B cell signaling agents, including ibrutinib, idelalisib, and the BCL-2 inhibitor venetoclax have become an integral part of therapy for patients with non-Hodgkin's lymphomas. The toxicity profiles of these medications is distinct from chemoimmunotherapy. Here, we will review the mechanism of action of t...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-018-0694-x
更新日期：2018-04-11 00:00:00
abstract：PURPOSE OF REVIEW:Immune checkpoint inhibitors (ICI) are only effective in a subset of patients. Here, we will review the rationale and data supporting the combination of PD-1 pathway inhibition with recombinant cytokines and neoantigen-based cancer vaccines that can potentially increase the number of patients who will...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-018-0738-2
更新日期：2018-11-15 00:00:00
